## Jan J Piek

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1756971/publications.pdf

Version: 2024-02-01

57758 42399 9,872 235 44 92 citations h-index g-index papers 240 240 240 8394 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine, 2017, 377, 2419-2432.	27.0	764
2	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. New England Journal of Medicine, 2017, 376, 1824-1834.	27.0	742
3	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon PumpÂin Cardiogenic Shock After AcuteÂMyocardial Infarction. Journal of the American College of Cardiology, 2017, 69, 278-287.	2.8	612
4	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet, The, 2016, 388, 2479-2491.	13.7	451
5	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. New England Journal of Medicine, 2017, 376, 2319-2328.	27.0	363
6	Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate Severity. Circulation: Cardiovascular Interventions, 2014, 7, 301-311.	3.9	322
7	One-Year Outcomes after PCI Strategies in Cardiogenic Shock. New England Journal of Medicine, 2018, 379, 1699-1710.	27.0	303
8	Multicenter Core Laboratory Comparison of the Instantaneous Wave-Free Ratio and Resting P /P With Fractional Flow Reserve. Journal of the American College of Cardiology, 2014, 63, 1253-1261.	2.8	301
9	Percutaneous Intervention for ConcurrentÂChronic Total Occlusions inÂPatients WithÂSTEMI. Journal of the American College of Cardiology, 2016, 68, 1622-1632.	2.8	300
10	Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. European Heart Journal, 2015, 36, 3134-3146.	2,2	177
11	Prospective Assessment of the DiagnosticÂAccuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance. JACC: Cardiovascular Interventions, 2015, 8, 824-833.	2.9	172
12	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	2.9	159
13	Baseline Instantaneous Wave-Free Ratio as a Pressure-Only Estimation of Underlying Coronary Flow Reserve. Circulation: Cardiovascular Interventions, 2014, 7, 492-502.	3.9	152
14	Early Intravenous Beta-Blockers in PatientsÂWith ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 67, 2705-2715.	2.8	144
15	Fundamentals in clinical coronary physiology: why coronary flow is more important than coronary pressure. European Heart Journal, 2015, 36, 3312-3319.	2.2	131
16	Coronary pressure and flow relationships in humans: phasic analysis of normal and pathological vessels and the implications for stenosis assessment: a report from the Iberian–Dutch–English (IDEAL) collaborators. European Heart Journal, 2015, 37, 2069-2080.	2.2	129
17	Fractional flow reserve as a surrogate for inducible myocardial ischaemia. Nature Reviews Cardiology, 2013, 10, 439-452.	13.7	127
18	Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention, 2015, 10, 1160-1168.	3.2	118

#	Article	IF	CITATIONS
19	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2018, 11, 1437-1449.	2.9	111
20	Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses. Journal of Clinical Investigation, 2019, 129, 4922-4936.	8.2	109
21	Genousâ,,¢ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. European Heart Journal, 2010, 31, 1055-1064.	2.2	106
22	Fractional Flow Reserve/InstantaneousÂWave-Free Ratio Discordance in Angiographically Intermediate CoronaryÂStenoses. JACC: Cardiovascular Interventions, 2017, 10, 2514-2524.	2.9	104
23	Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment. Heart, 2014, 100, 951-959.	2.9	102
24	Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. European Heart Journal, 2019, 40, 456-465.	2.2	100
25	Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Predicts Hemodynamic Outcome In Humans WithÂCoronary Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 757-767.	2.9	95
26	Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. Nature Reviews Cardiology, 2020, 17, 427-450.	13.7	94
27	The Prognostic Value of Bleeding Academic Research Consortium (BARC)-Defined BleedingÂComplications in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 1866-1875.	2.8	93
28	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. American Heart Journal, 2016, 172, 160-169.	2.7	93
29	Immediate and Long-Term Effect of Balloon Angioplasty or Stent Implantation on the Absolute and Relative Coronary Blood Flow Velocity Reserve. Circulation, 1998, 98, 2133-2140.	1.6	91
30	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the TreatmentÂof Any In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 275-283.	2.9	88
31	Impact of Aortic Valve Stenosis on Coronary Hemodynamics and the Instantaneous Effect of Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002443.	3.9	<b>7</b> 5
32	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	2.8	71
33	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. JACC: Cardiovascular Interventions, 2019, 12, 2064-2075.	2.9	71
34	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	3.9	71
35	Real-time use of instantaneous wave–free ratio: Results of the ADVISE in-practice: An international, multicenter evaluation of instantaneous wave–free ratio in clinical practice. American Heart Journal, 2014, 168, 739-748.	2.7	67
36	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. Frontiers in Cardiovascular Medicine, 2020, 7, 119.	2.4	65

#	Article	IF	CITATIONS
37	Imaging Systemic Inflammatory Networks in Ischemic Heart Disease. Journal of the American College of Cardiology, 2015, 65, 1583-1591.	2.8	64
38	Coronary Physiology During Exercise and Vasodilation in the Healthy Heart and in Severe Aortic Stenosis. Journal of the American College of Cardiology, 2016, 68, 688-697.	2.8	60
39	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. JACC: Cardiovascular Interventions, 2020, 13, 1617-1638.	2.9	60
40	Antiplatelet therapy following transcatheter aortic valve implantation. Heart, 2015, 101, 1118-1125.	2.9	56
41	Anxiety levels of patients undergoing coronary procedures in the catheterization laboratory. International Journal of Cardiology, 2017, 228, 926-930.	1.7	55
42	Arteriogenesis: Mechanisms and modulation of collateral artery development. Journal of Nuclear Cardiology, 2001, 8, 687-693.	2.1	54
43	Distal Embolization of Hydrophilic-Coating Material From Coronary Guidewires After Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2015, 8, e001816.	3.9	50
44	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
45	Efficacy of the RADPAD Protection Drape in Reducing Operators' Radiation Exposure in the Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	48
46	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. JACC: Cardiovascular Interventions, 2019, 12, 259-270.	2.9	46
47	Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention, 2016, 12, 1102-1107.	3.2	46
48	Elevated monocyte-specific type I interferon signalling correlates positively with cardiac healing in myocardial infarct patients but interferon alpha application deteriorates myocardial healing in rats. Basic Research in Cardiology, 2019, 114, 1.	5.9	44
49	Pharmacological Modulation of the Human Collateral Vascular Resistance in Acute and Chronic Coronary Occlusion Assessed by Intracoronary Blood Flow Velocity Analysis in an Angioplasty Model. Circulation, 1997, 96, 106-115.	1.6	42
50	Amsterdam Investigatorâ c'initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale	2.7	41
51	and study design. American Heart Journal, 2014, 167, 133-140. Incidence, Predictors, and Impact of Vascular Complications After Transfemoral Transcatheter Aortic Valve Implantation With the SAPIEN 3 Prosthesis. American Journal of Cardiology, 2018, 121, 1231-1238.	1.6	41
52	Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment–Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. Circulation, 2019, 139, 636-646.	1.6	40
53	Twoâ€year followâ€up of the genousâ,,¢ endothelial progenitor cell capturing stent versus the taxus liberté stent in patients with <i>De Novo</i> coronary artery lesions with a highâ€risk of restenosis. Catheterization and Cardiovascular Interventions, 2011, 78, 189-195.	1.7	38
54	Comparison of Doppler Flow Velocity and Thermodilution Derived Indexes of Coronary Physiology. JACC: Cardiovascular Interventions, 2022, 15, 1060-1070.	2.9	38

#	Article	IF	CITATIONS
55	Incidence and Potential Mechanism(s) ofÂPost-Procedural Rise of Cardiac BiomarkerÂin Patients With Coronary ArteryÂNarrowing After Implantation of anÂEverolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. JACC: Cardiovascular Interventions, 2015, 8, 1053-1063.	2.9	36
56	Transcatheter Replacement of Stenotic Aortic Valve Normalizes Cardiac–Coronary Interaction by Restoration of Systolic Coronary Flow Dynamics as Assessed by Wave Intensity Analysis. Circulation: Cardiovascular Interventions, 2016, 9, e002356.	3.9	36
57	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis, 2020, 295, 45-53.	0.8	36
58	Clinical Events After Deferral of LADÂRevascularization Following PhysiologicalÂCoronaryÂAssessment. Journal of the American College of Cardiology, 2019, 73, 444-453.	2.8	35
59	Influence of the amount of myocardium subtended to a coronary stenosis on the index of microcirculatory resistance. Implications for the invasive assessment of microcirculatory function in ischaemic heart disease. EuroIntervention, 2017, 13, 944-952.	3.2	33
60	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 77, 2761-2773.	2.8	32
61	Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. , 2022, 1, 28-44.		32
62	Predictors of outcome in patients undergoing MitraClip implantation: An aid to improve patient selection. International Journal of Cardiology, 2015, 189, 238-243.	1.7	31
63	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2572-2584.	2.8	31
64	Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2035-2040.	1.6	29
65	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. European Heart Journal, 2018, 39, 3381-3389.	2.2	29
66	Mitral Inflow Patterns after MitraClip Implantation at Rest and during Exercise. Journal of the American Society of Echocardiography, 2014, 27, 24-31.e1.	2.8	28
67	Contribution of Age-Related Microvascular Dysfunction to AbnormalÂCoronary. JACC: Cardiovascular Interventions, 2020, 13, 20-29.	2.9	28
68	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Expert Review of Medical Devices, 2019, 16, 211-228.	2.8	27
69	Transfemoral TAVR in Nonagenarians. JACC: Cardiovascular Interventions, 2019, 12, 911-920.	2.9	27
70	Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve–Guided Revascularization Strategy. JACC: Cardiovascular Interventions, 2019, 12, 2035-2046.	2.9	26
71	Impact of postâ€procedural minimal stent area on 2â€year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26
72	Relationship between FFR, CFR and coronary microvascular resistance – Practical implications for FFR-guided percutaneous coronary intervention. PLoS ONE, 2019, 14, e0208612.	2.5	26

#	Article	IF	Citations
73	Physiological assessment of left main coronary artery disease. EuroIntervention, 2017, 13, 820-827.	3.2	26
74	Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention, 2018, 14, e426-e433.	3.2	26
75	The SYNTAX score on its way out or â€  towards artificial intelligence: part I. EuroIntervention, 2020, 16, 44-59.	3.2	26
76	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	1.6	25
77	Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve–Guided Strategy in Patients With or Without Type 2 Diabetes. JAMA Cardiology, 2019, 4, 857.	6.1	25
78	Artificial Intelligence for Aortic Pressure Waveform Analysis During CoronaryÂAngiography. JACC: Cardiovascular Interventions, 2019, 12, 2093-2101.	2.9	24
79	Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. EuroIntervention, 2018, 14, e570-e579.	3.2	24
80	Safety and efficacy of drug eluting stents in patients with spontaneous coronary artery dissection. International Journal of Cardiology, 2017, 238, 105-109.	1.7	22
81	Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques. PLoS ONE, 2017, 12, e0187767.	2.5	22
82	Invasive minimal Microvascular Resistance Is a New Index to Assess Microcirculatory Function Independent of Obstructive Coronary Artery Disease. Journal of the American Heart Association, 2016, 5, .	3.7	21
83	Guideline-defined futility or patient-reported outcomes to assess treatment success after TAVI: what to use? Results from a prospective cohort study with long-term follow-up. Open Heart, 2018, 5, e000879.	2.3	21
84	Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS ONE, 2015, 10, e0137035.	2.5	21
85	Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity. Basic Research in Cardiology, 2017, 112, 61.	5.9	20
86	Impact of Coronary Remodeling on Fractional Flow Reserve. Circulation, 2018, 137, 747-749.	1.6	20
87	Strain analysis is superior to wall thickening in discriminating between infarcted myocardium with and without microvascular obstruction. European Radiology, 2018, 28, 5171-5181.	4.5	20
88	Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses. Circulation: Cardiovascular Interventions, 2019, 12, e008263.	3.9	20
89	CT determined psoas muscle area predicts mortality in women undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2019, 93, E248-E254.	1.7	20
90	Impact of Center Experience on Patient Radiation Exposure During Transradial Coronary Angiography and Percutaneous Intervention: A Patient‣evel, International, Collaborative, Multi enter Analysis. Journal of the American Heart Association, 2016, 5, .	3.7	19

#	Article	IF	CITATIONS
91	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
92	Clinical Relevance of Ischemia with Nonobstructive Coronary Arteries According to Coronary Microvascular Dysfunction. Journal of the American Heart Association, 2022, 11, e025171.	3.7	19
93	Percutaneous Mitral Valve Repair Preserves Right Ventricular Function. Journal of the American Society of Echocardiography, 2014, 27, 1098-1106.	2.8	18
94	Long term outcome after mononuclear bone marrow or peripheral blood cells infusion after myocardial infarction. Heart, 2015, 101, 363-368.	2.9	18
95	Long-term left ventricular remodelling after revascularisation for ST-segment elevation myocardial infarction as assessed by cardiac magnetic resonance imaging. Open Heart, 2017, 4, e000569.	2.3	18
96	Cerebral protection devices during transcatheter aortic valve implantation. Trends in Cardiovascular Medicine, 2018, 28, 412-418.	4.9	18
97	Comparison of Outcomes of Transfemoral Aortic Valve Implantation in Patients <90 With Those >90 Years of Age. American Journal of Cardiology, 2018, 121, 1581-1586.	1.6	18
98	Fractional Flow Reserve or Coronary Flow Reserve for the Assessment of Myocardial Perfusion. Current Cardiology Reports, 2018, 20, 77.	2.9	18
99	Non-hyperaemic coronary pressure measurements to guide coronary interventions. Nature Reviews Cardiology, 2020, 17, 629-640.	13.7	18
100	The SYNTAX score on its way out or … towards artificial intelligence: part II. EuroIntervention, 2020, 16, 60-75.	3.2	18
101	DAPT Score and the Impact of TicagrelorÂMonotherapy During the Second Year After PCI. JACC: Cardiovascular Interventions, 2020, 13, 634-646.	2.9	17
102	First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. EuroIntervention, 2018, 13, 2026-2035.	3.2	17
103	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. American Heart Journal, 2020, 225, 60-68.	2.7	16
104	A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. EuroIntervention, 2018, 14, e1306-e1315.	3.2	16
105	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention, 2022, 18, e377-e388.	3.2	16
106	Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous $\hat{l}^2$ -blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention. American Heart Journal, 2014, 168, 661-666.	2.7	15
107	Predictors and prognostic consequence of gastrointestinal bleeding in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2015, 184, 128-134.	1.7	15
108	The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the) Tj ETQq0 Interventions, 2016, 9, .	0 0 rgBT / 3.9	Overlock 10 7 15

Interventions, 2016, 9, .

#	Article	IF	CITATIONS
109	Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect— combined pressure and Doppler FLOW velocity measurements (DEFINE-FLOW) trial: Rationale and trial design. American Heart Journal, 2020, 222, 139-146.	2.7	15
110	Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With STâ€Segment–Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Longâ€Term Followâ€Up of the REDUCEâ€MVI Trial. Journal of the American Heart Association, 2020, 9, e014411.	3.7	15
111	State of the art: pressure wire and coronary functional assessment. EuroIntervention, 2017, 13, 666-679.	3.2	15
112	Basal stenosis resistance index derived from simultaneous pressure and flow velocity measurements. EuroIntervention, 2016, 12, e199-e207.	3.2	15
113	Mitral regurgitation prior to transcatheter aortic valve implantation influences survival but not symptoms. International Journal of Cardiology, 2016, 204, 95-100.	1.7	14
114	Abnormal haemodynamic postural response in patients with chronic heart failure. ESC Heart Failure, 2017, 4, 146-153.	3.1	14
115	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020, 109, 1125-1139.	3.3	14
116	Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial. EuroIntervention, 2018, 14, e434-e442.	<b>3.</b> 2	14
117	Diagnostic cutoff for pressure drop coefficient in relation to fractional flow reserve and coronary flow reserve: A Patient‣evel Analysis. Catheterization and Cardiovascular Interventions, 2016, 87, 273-282.	1.7	13
118	Impact of Potentially Malignant Incidental Findings by Computed Tomographic Angiography on Long-Term Survival After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 994-1001.	1.6	13
119	Procedural Outcome and Midterm Survival of Lower Risk Transfemoral Transcatheter Aortic Valve Implantation Patients Treated With the SAPIEN XT or SAPIEN 3 Device. American Journal of Cardiology, 2018, 121, 856-861.	1.6	13
120	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. European Radiology, 2020, 30, 600-608.	4.5	13
121	Cerebral Blood Flow in Patients with Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation. Journal of the American Geriatrics Society, 2021, 69, 494-499.	2.6	13
122	Invasive and non-invasive assessment of ischaemia in chronic coronary syndromes: translating pathophysiology to clinical practice. European Heart Journal, 2022, 43, 105-117.	2.2	13
123	NT-pro-BNP is associated with inducible myocardial ischemia in mildly symptomatic type 2 diabetic patients. International Journal of Cardiology, 2010, 145, 295-296.	1.7	12
124	Diagnostic Accuracy of Coronary CT Angiography forÂthe Evaluation of Bioresorbable Vascular Scaffolds. JACC: Cardiovascular Imaging, 2018, 11, 722-732.	<b>5.</b> 3	12
125	Aortic valve calcification volumes and chronic brain infarctions in patients undergoing transcatheter aortic valve implantation. International Journal of Cardiovascular Imaging, 2019, 35, 2123-2133.	1.5	12
126	Myocardial fibrosis predicts adverse outcome after MitraClip implantation. Catheterization and Cardiovascular Interventions, 2019, 93, 1146-1149.	1.7	12

#	Article	IF	Citations
127	Older coronary thrombus is an independent predictor of 1â€year mortality in acute myocardial infarction. European Journal of Clinical Investigation, 2016, 46, 501-510.	3.4	11
128	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. Open Heart, 2018, 5, e000810.	2.3	11
129	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial. EuroIntervention, 2019, 15, 603-606.	3.2	11
130	Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. EuroIntervention, 2016, 12, e557-e565.	3.2	11
131	Coronary flow capacity: concept, promises, and challenges. International Journal of Cardiovascular Imaging, 2017, 33, 1033-1039.	1.5	10
132	Sufentanil–medetomidine anaesthesia compared with fentanyl/fluanisone–midazolam is associated with fewer ventricular arrhythmias and death during experimental myocardial infarction in rats and limits infarct size following reperfusion. Laboratory Animals, 2018, 52, 271-279.	1.0	10
133	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. Structural Heart, 2018, 2, 53-57.	0.6	10
134	Quantification of Myocardial Mass Subtended by a Coronary Stenosis Using Intracoronary Physiology. Circulation: Cardiovascular Interventions, 2019, 12, e007322.	3.9	10
135	Pressure-derived estimations of coronary flow reserve are inferior to flow-derived coronary flow reserve as diagnostic and risk stratification tools. International Journal of Cardiology, 2019, 279, 6-11.	1.7	10
136	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	3.0	10
137	A Prospective Multicenter Randomized Trial to Assess the Effectiveness of the MagicTouch Sirolimus-Coated Balloon in Small Vessels: Rationale and Design of the TRANSFORM I Trial. Cardiovascular Revascularization Medicine, 2021, 25, 29-35.	0.8	10
138	Assessing the Haemodynamic Impact of Coronary Artery Stenoses: Intracoronary Flow Versus Pressure Measurements. European Cardiology Review, 2018, 13, 46.	2.2	10
139	Collateral flow velocity alterations in the supply and receiving coronary arteries during angioplasty for total coronary occlusion. Catheterization and Cardiovascular Diagnosis, 1995, 34, 167-174.	0.3	9
140	Detection and quantification methods of monocyte homing in coronary vasculature with an imaging cryomicrotome. Journal of Molecular and Cellular Cardiology, 2014, 76, 196-204.	1.9	9
141	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. Journal of Thrombosis and Thrombolysis, 2016, 41, 441-451.	2.1	9
142	Contribution of Age and Intimal Lesion Morphology to Coronary Artery Wall Mechanics in Coronary Artery Disease. Clinical Science, 1995, 89, 239-246.	4.3	8
143	Coronary Flow Capacity to Identify Stenosis Associated With Coronary Flow Improvement After Revascularization: A Combined Analysis From DEFINE FLOW and IDEAL. Journal of the American Heart Association, 2020, 9, e016130.	3.7	8
144	Clinical outcomes of bioabsorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: two-year follow-up of the DESSOLVE III trial. EuroIntervention, 2020, 15, e1366-e1374.	3.2	8

#	Article	IF	Citations
145	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. EuroIntervention, 2016, 12, 423-430.	3.2	8
146	Tissue ablation and gas formation of two excimer laser systems: An in vitro evaluation on porcine aorta., 1996, 18, 197-205.		7
147	Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1956-1963.	6.4	7
148	Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention. Open Heart, 2018, 5, e000833.	2.3	7
149	p47phox-Dependent Reactive Oxygen Species Stimulate Nuclear Translocation of the FoxO1 Transcription Factor During Metabolic Inhibition in Cardiomyoblasts. Cell Biochemistry and Biophysics, 2018, 76, 401-410.	1.8	7
150	Transient ST-segment elevation and coronary flow. European Heart Journal, 2019, 40, 2463-2464.	2.2	7
151	Individual Lesion-Level Meta-Analysis Comparing Various Doses of Intracoronary Bolus Injection of Adenosine With Intravenous Administration of Adenosine for Fractional Flow Reserve Assessment. Circulation: Cardiovascular Interventions, 2020, 13, e007893.	3.9	7
152	Estimation of Intraglomerular Pressure Using Invasive Renal Arterial Pressure and Flow Velocity Measurements in Humans. Journal of the American Society of Nephrology: JASN, 2020, 31, 1905-1914.	6.1	7
153	Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. Journal of Clinical Medicine, 2021, 10, 4005.	2.4	7
154	Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication. European Heart Journal, 2016, 37, 1104-1112.	2.2	6
155	Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography. Catheterization and Cardiovascular Interventions, 2018, 92, E106-E114.	1.7	6
156	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
157	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
158	Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial). American Journal of Cardiology, 2021, 151, 30-38.	1.6	6
159	Physiology-guided myocardial revascularisation in complex multivessel coronary artery disease: beyond the 2014 ESC/EACTS guidelines on myocardial revascularisation. Open Heart, 2015, 2, e000308.	2.3	5
160	Monocytic microRNA profile associated with coronary collateral artery function in chronic total occlusion patients. Scientific Reports, 2017, 7, 1532.	3.3	5
161	What does the future hold for novel intravascular imaging devices: a focus on morphological and physiological assessment of plaque. Expert Review of Medical Devices, 2017, 14, 985-999.	2.8	5
162	Objective Identification of Intermediate Lesions Inducing Myocardial Ischemia Using Sequential Intracoronary Pressure and Flow Measurements. Journal of the American Heart Association, 2020, 9, e015559.	3.7	5

#	Article	IF	Citations
163	Microvascular dysfunction following ST-elevation myocardial infarction and its recovery over time. EuroIntervention, 2017, 13, e578-e584.	3.2	5
164	One-year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion. EuroIntervention, 2018, 14, 688-691.	3.2	5
165	Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). EuroIntervention, 2018, 14, e1057-e1066.	3.2	5
166	Assessment of collateral flow during balloon coronary occlusion by intracoronary blood flow velocity analysis. Catheterization and Cardiovascular Diagnosis, 1995, 35, 362-367.	0.3	4
167	Angioplasty of chronic total coronary occlusions with the use of six French guiding catheters. , 1997, 40, 255-260.		4
168	Evaluation of the long-term functional outcome assessed by myocardial perfusion scintigraphy following excimer laser angioplasty compared to balloon angioplasty in longer coronary lesions. International Journal of Cardiovascular Imaging, 2000, 16, 267-277.	0.6	4
169	Resting Indices of Coronary Lesion Severity. Circulation: Cardiovascular Interventions, 2016, 9, e003747.	3.9	4
170	Evaluation of lesion flow coefficient for the detection of coronary artery disease in patient groups from two academic medical centers. Cardiovascular Revascularization Medicine, 2018, 19, 348-354.	0.8	4
171	Fiveâ€year followâ€up of the endothelial progenitor cell capturing stent versus the paxlitaxelâ€eluting stent in de novo coronary lesions with a high risk of coronary restenosis. Catheterization and Cardiovascular Interventions, 2018, 91, 1212-1218.	1.7	4
172	Authorship: from credit to accountability. Reflections from the Editors' Network. Basic Research in Cardiology, 2019, 114, 23.	5.9	4
173	Paclitaxelâ€eluting balloon versus everolimusâ€eluting stent in patients with diabetes mellitus and inâ€stent restenosis: Insights from the randomized DARE trial. Catheterization and Cardiovascular Interventions, 2019, 93, 216-221.	1.7	4
174	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drugâ€eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. Catheterization and Cardiovascular Interventions, 2020, 95, 89-96.	1.7	4
175	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. International Journal of Cardiology, 2020, 300, 93-98.	1.7	4
176	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vsÂMultivessel PCI in Cardiogenic Shock Trial. Chest, 2021, 159, 1415-1425.	0.8	4
177	Transient ST-elevation myocardial infarction versus persistent ST-elevation myocardial infarction. An appraisal of patient characteristics and functional outcome. International Journal of Cardiology, 2021, 336, 22-28.	1.7	4
178	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study. American Heart Journal, 2021, 239, 19-26.	2.7	4
179	Left ventricular four-dimensional blood flow distribution, energetics, and vorticity in chronic myocardial infarction patients with/without left ventricular thrombus. European Journal of Radiology, 2022, 150, 110233.	2.6	4
180	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	1.7	4

#	Article	IF	CITATIONS
181	Neovascularity related to mural thrombus in endomyocardial fibrosis. International Journal of Cardiovascular Imaging, 1999, 15, 205-207.	0.6	3
182	Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback and Virtual Revascularization. JACC: Cardiovascular Interventions, 2014, 7, 1397-1399.	2.9	3
183	The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stent. European Heart Journal Quality of Care & Dinical Outcomes, 2016. 2. 108-116.	4.0	3
184	The current status of antiplatelet therapy in patients undergoing transcatheter aortic valve implantation. Journal of Thoracic Disease, 2017, 9, 3652-3655.	1.4	3
185	First-in-Man Trial of SiO <sub>2</sub> Inert-Coated Bare Metal Stent System in Native Coronary Stenosis ― The AXETIS FIM Trial ―. Circulation Journal, 2018, 82, 477-485.	1.6	3
186	Discordance between pressure drift after wire pullback and intracoronary distal pressure offset affects stenosis physiology appraisal. International Journal of Cardiology, 2019, 277, 29-34.	1.7	3
187	Authorship: from credit to accountability. Reflections from the Editors' Network. Clinical Research in Cardiology, 2019, 108, 723-729.	3.3	3
188	Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent. Atherosclerosis, 2020, 312, 79-89.	0.8	3
189	Differential Prognostic Value of Revascularization for Coronary Stenosis With Intermediate FFR by Coronary FlowAReserve. JACC: Cardiovascular Interventions, 2022, 15, 1033-1043.	2.9	3
190	Early lumen diameter loss after percutaneous transluminal coronary angioplasty is related to coronary plaque burden: a role for viscous plaque properties in early lumen diameter loss. International Journal of Cardiovascular Imaging, 2001, 17, 111-121.	0.6	2
191	The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting ScaffoldÂand Metallic Everolimus-Eluting Stent onÂClinical Outcomes inÂtheÂABSORB Il Trial. JACC: Cardiovascular Interventions, 2018, 11, 1013-1015.	2.9	2
192	Diastolic-systolic velocity ratio to detect coronary stenoses under physiological resting conditions: a mechanistic study. Open Heart, 2019, 6, e000968.	2.3	2
193	Letter by Kern et al Regarding Article, "Effects of Impella on Coronary Perfusion in Patients With Critical Coronary Artery Stenosis― Circulation: Cardiovascular Interventions, 2019, 12, e007751.	3.9	2
194	MicroRNAs to take the place of collateral flow index measurements and Rentrop scoring?â€"Reply to Papageorgiou et al Annals of Translational Medicine, 2016, 4, 297-297.	1.7	2
195	Respirationâ€related variations in Pd/Pa ratio and fractional flow reserve in resting conditions and during intravenous adenosine administration. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	2
196	Prognostic value of microvascular resistance and its association to fractional flow reserve: a DEFINE-FLOW substudy. Open Heart, 2022, 9, e001981.	2.3	2
197	Subacute narrowing of the left main coronary artery following directional atherectomy for proximal obstructive coronary artery disease., 1997, 40, 361-363.		1
198	An analogue laser optical disc in comparison with cinefilm for visual analysis of coronary narrowings before and after coronary angioplasty. International Journal of Cardiovascular Imaging, 1998, 14, 19-26.	0.6	1

#	Article	IF	Citations
199	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ°' > A mutation. , 1998, 44, 427-430.		1
200	Is fitness training always good for your health?. Catheterization and Cardiovascular Interventions, 2001, 52, 110-111.	1.7	1
201	1-Year Clinical Performance of COMBO Stent Versus XienceÂStent in All-Comers Patients With Coronary ArteryÂDisease. JACC: Cardiovascular Interventions, 2018, 11, 102-103.	2.9	1
202	Coronary Flow Measurements in ClinicalÂPractice. JACC: Cardiovascular Interventions, 2018, 11, 738-740.	2.9	1
203	Go With the Flow When Instantaneous Wave-Free Ratio-Fractional Flow Reserve Discordance Occurs. JACC: Cardiovascular Interventions, 2018, 11, 2435-2436.	2.9	1
204	Authorship: From credit to accountability. Reflections from the Editors' Network. Revista Portuguesa De Cardiologia, 2019, 38, 519-525.	0.5	1
205	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. Circulation Journal, 2019, 83, 556-566.	1.6	1
206	Threeâ€year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimusâ€eluting stent in routine PCI in patients with diabetes mellitus— AIDA subâ€study. Catheterization and Cardiovascular Interventions, 2020, 98, 713-720.	1.7	1
207	The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program. Future Cardiology, 2020, 17, 593-607.	1.2	1
208	External validation of the GRACE risk score 2.0 in the contemporary allâ€comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2021, 98, E513-E522.	1.7	1
209	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ°' > A mutation. Catheterization and Cardiovascular Diagnosis, 1998, 44, 427-430.	0.3	1
210	Coronary physiological parameters at a crossroads. EuroIntervention, 2017, 13, e145-e148.	3.2	1
211	Model prediction of subendocardial perfusion in the presence of an epicardial coronary artery stenosis. FASEB Journal, 2008, 22, 1152.12.	0.5	1
212	Authorship: From Credit to Accountability Reflections From the Editors´ Network. Anatolian Journal of Cardiology, 2019, 21, 281-286.	0.9	1
213	Preclinical evaluation of a thin-strut bioresorbable scaffold (ArterioSorb): acute-phase invasive imaging assessment and hemodynamic implication EuroIntervention, 2020, 16, e141-e146.	3.2	1
214	Phasic flow patterns of right versus left coronary arteries in patients undergoing clinical physiological assessment. EuroIntervention, 2022, 17, 1260-1270.	3.2	1
215	How to set up regional STEMI networks: a "Stent - Save a life!" initiative. EuroIntervention, 2022, 17, 1313-1317.	3.2	1
216	Differential Impact of Coronary Revascularization on Long-Term Clinical Outcome According to Coronary Flow Characteristics: Analysis of the International ILIAS Registry. Circulation: Cardiovascular Interventions, 2022, 15, .	3.9	1

#	Article	IF	CITATIONS
217	Pressure recordings in coexistent fixed congenital membraneous and hypertrophic subaortic stenosis. Catheterization and Cardiovascular Diagnosis, 1995, 36, 262-264.	0.3	O
218	Response to Michiels et al and Sen et al Regarding Article, "Diagnostic Accuracy of Combined Intracoronary Pressure and Flow Velocity Information During Baseline Conditions: Adenosine-Free Assessment of Functional Coronary Lesion Severity― Circulation: Cardiovascular Interventions, 2012, 5, .	3.9	0
219	Accelerate and Decelerate in Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 241-243.	2.9	0
220	Adenosine-Dependent Vasodilation and the Quest for "Maximal―Hyperemia. JACC: Cardiovascular Interventions, 2016, 9, 200-201.	2.9	0
221	Recurrent myocardial infarction in a 47â€yearâ€old woman with a mechanical mitral valve prosthesis: Atherosclerosis, embolism, or spasm?. Catheterization and Cardiovascular Interventions, 2018, 91, 267-270.	1.7	0
222	Recurrent myocardial infarction in an aneurysmal coronary artery managed with stent grafts. Coronary Artery Disease, 2018, 29, 171-173.	0.7	0
223	Response to the letter by Dr. Horszczaruk: Pressure-bounded coronary flow reserve – Yet a meaningless concept?. International Journal of Cardiology, 2019, 293, 60.	1.7	0
224	Authorship: From Credit to Accountability. Reflections From the Editors Network. Revista Colombiana De Cardiologia, 2019, 26, 117-124.	0.1	0
225	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	0
226	Usefulness of Proximal Coronary Wave Speed for Wave Intensity Analysis in Diseased Coronary Vessels. Frontiers in Cardiovascular Medicine, 2020, 7, 133.	2.4	0
227	Wave intensity analysis of coronary pressure and velocity for studying coronaryâ€ventricular interactions. FASEB Journal, 2008, 22, 1152.14.	0.5	0
228	Physiological Significance of a Coronary Stenosis Assessed from Pulsatile Resistance Index at Baseline Flow. FASEB Journal, 2009, 23, 1032.8.	0.5	0
229	Effect of the Valsalva maneuver on cardiacâ€coronary interaction studied by coronary wave intensity in humans. FASEB Journal, 2010, 24, 1034.10.	0.5	0
230	Imaging of Single Fluorescent Cells for 3â€D Quantification of Neovascularization in Ischemic Myocardial Tissue. FASEB Journal, 2012, 26, 682.15.	0.5	0
231	Temporal response of monocytes during progressive coronary artery occlusion (1071.7). FASEB Journal, 2014, 28, 1071.7.	0.5	0
232	Measurement of Coronary Flow Reserve in the Catheterization Laboratory., 2017,, 159-171.		0
233	Authorship: From credit to accountability – Reflections from the Editors' network. Archivos De Cardiolog�a De M�xico (English Ed Internet), 2019, 89, 93-99.	0.0	0
234	AutorÃa: del crédito a la responsabilidad - Reflexiones de la red de editores. Archivos De Cardiologia De Mexico, 2019, 89, 105-111.	0.2	O

#	Article	IF	CITATIONS
235	Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial. Open Heart, 2020, 7, .	2.3	0